Multicenter, placebo‐controlled, double‐blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy

BACKGROUND: The current randomized, double‐blind, phase 2 study assessed the efficacy and safety profile of a single intravenous administration of fosnetupitant, a neurokinin 1 receptor antagonist prodrug, for the prevention of chemotherapy‐induced nausea and vomiting in Japanese patients receiving...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Sugawara, Shunichi, Inui, Naoki, Kanehara, Masashi, Morise, Masahiro, Yoshimori, Kozo, Kumagai, Toru, Fukui, Tomoya, Minato, Koichi, Iwashima, Akira, Takeda, Yuichiro, Kubota, Kaoru, Saeki, Toshiaki, Tamura, Tomohide
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6900104/
https://ncbi.nlm.nih.gov/pubmed/31381152
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32429
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados